8-K ·Filed Apr 20, 2026

WLK

WESTLAKE CORP
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001193125-26-164225
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor upcoming earnings calls for Baksht's strategic direction and capital allocation priorities. The contested proxy fight context suggests heightened investor scrutiny—watch for changes in governance or capital return policies.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
WLK ▼ -33.23% at T+60d
NEUTRAL call ✗ call lost -33.23% · α vs SPY -39.85% · entry $115.44 → $77.08
Entry anchored
Apr 20, 03:59 PM ET
via exchange tick
T+1d
-1.58%
call -1.58% · α -2.60%
$113.62
settled 5mo ago
T+5d
-4.65%
call -4.65% · α -5.74%
$110.07
settled 5mo ago
T+20d
-20.77%
call -20.77% · α -25.69%
$91.46
settled 5mo ago
T+60d
-33.23%
call -33.23% · α -39.85%
$77.08
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Westlake Corporation appointed Jonathan H. Baksht as Senior Vice President and Chief Financial Officer, effective June 15, 2026. He succeeds M. Steven Bender, who will retire after 21 years and transition to Special Advisor. The move follows a contested proxy fight, adding scrutiny to the leadership transition.

Key Facts

  • Jonathan H. Baksht appointed CFO effective June 15, 2026
  • Baksht receives $200,000 sign-on cash award and $1.8M in RSUs vesting in 2029
  • Base salary set at $832,000 with 90% target bonus and 275% long-term incentive target
  • Outgoing CFO M. Steven Bender retiring after 21 years, transitioning to Special Advisor
  • Appointment announced via Regulation FD disclosure (Item 7.01)
  • Follows contested proxy fight (DEFA14A filed 18 days prior)

Financial Impact

Approximately $2.0M in initial compensation (cash + RSUs) for new CFO

compensation expenseshare dilution

Risk Factors

  • Leadership transition risk during integration period
  • Potential strategic shift under new CFO following proxy contest
  • RSU vesting creates retention dependency through 2029

Market Snapshot

Exchange
NYSE
Sector
Industrial Organic Chemicals

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-164225
Document: d28569dex991.htm0001193125-26-164225
Document: 0001193125-26-164225-index-headers.html0001193125-26-164225
Document: 0001193125-26-164225-index.html0001193125-26-164225
Document: 0001193125-26-164225.txt0001193125-26-164225
15 reports for WLK
Performance horizon
100% Hit rate 5 of 5 directional calls best @ T+60▲ +36.80%Apr 14, 2026
Filters
Rows
Reports for WLK — sortable, filterable
TypeNow
Aug 31, 2026
4w ago
8-K
NEUTRAL ★ 2/10
$74.23 $62.31▼ −16.06%▼ −16.38%$63.50 (−14.46%)
Aug 14, 2026
6w ago
Press Release
NEUTRAL ★ 2/10
$78.21 $70.02▼ −10.47%▼ −8.49%$63.50 (−18.81%)
Aug 4, 2026
8w ago
8-K
BULLISH ★ 6/10
$80.63 $74.23▼ −7.94%▼ −6.70%$63.50 (−21.25%)
Jul 21, 2026
10w ago
Press Release
BEARISH ★ 7/10
$76.22 $77.52▼ −1.71%▲ +0.86%$63.50 (+16.69%)
Jun 15, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$84.33 $77.04▼ −8.64%▼ −8.84%$63.50 (−24.70%)
Jun 14, 2026
15w ago
Institutional Cluster
MIXED ★ 5/10
$87.45 $76.07▼ −13.01%▼ −12.26%$63.50 (−27.39%)
May 5, 2026
21w ago
8-K
BEARISH ★ 7/10
$104.29 $86.83▲ +16.74%▲ +21.70%$63.50 (+39.11%)
Apr 20, 2026
23w ago
8-K
NEUTRAL ★ 4/10
$115.44 $91.46▼ −20.77%▼ −25.69%$63.50 (−44.99%)
Apr 14, 2026
24w ago
8-K
BEARISH ★ 7/10
$117.84 $97.56▲ +17.21%▲ +23.51%$63.50 (+46.11%)
Apr 6, 2026
25w ago
8-K
NEUTRAL ★ 4/10
$119.51 $114.07▼ −4.55%▼ −13.53%$63.50 (−46.87%)
Showing 10 of 15

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access